Johnson & Johnson, an American multinational pharmaceutical, biotechnology, and medical technologies corporation, completed the acquisition of Yellow Jersey Therapeutics, which holds assets relating to NM26, an investigational first-in-class bi-specific antibody for the treatment of atopic dermatitis, from Numab Therapeutics, a developer of immunotherapies for inflammation and cancer, for $1.25bn. “Nearly three-quarters of people with AD are not achieving remission with currently available treatments3. The unmet need is high, and we must do better for patients. Our investment in NM26, and other bispecific antibodies, is another important step towards our mission of durable, symptom-free remission for all patients living with immune-mediated diseases,” Candice Long, Johnson & Johnson Worldwide Vice President, Immunology.